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ABSTRACT 
Objective: In situ gels are suitable to overcome problems of immediate release and short gastrointestinal residence of liquids. These systems are 
liquids before administration and on contact with gastric contents are converted to gel. The present work deals with the formulation, evaluation and 
optimization of pH triggered floating oral in situ gel of Itopride hydrochloride by using sodium alginate as a gelling polymer and HPMC K100M as a 
release retardant polymer. 
Methods: A 32 factorial designs was carried out and the effect of variation in concentrations of sodium alginate and calcium carbonate on percent 
drug release at 1 h, 6 h, gel strength and T50% 
Results: The results of a 3
i. e. time required for the release 50 % of loaded drug was evaluated. The gels were studied for their 
viscosity, in vitro buoyancy and drug release, in vitro gelling capacity, density, gel strength.  
2 full factorial design revealed that the concentration of sodium alginate and concentration of calcium carbonate 
significantly affected the dependent variables. A controlled release profile was observed for these formulations. The dissolution data were fitted to 
various kinetic models which indicated diffusion controlled release profile. In vivo studies revealed higher Tmax of gel compared to plain drug which 
is suggestive of slower absorption. However, the AUC0-12 h
Conclusion: Floating oral in situ gelling system of amoxicillin can be formulated using sodium alginate as a gelling polymer to sustain the drug 
release for 12 h with diffusion controlled release kinetics. 
 was found to be nearly 90% higher than plain drug. Thus, bioavailability was found to be 
increased with in situ gel of Itopride hydrochloride.  
Keywords: Gastro retentive drug delivery, Oral in situ gel, Sodium alginate, Calcium carbonate. 
 
INTRODUCTION 
Oral administration is a most convenient and preferred means of 
any drug delivery to the systemic circulation. Oral controlled release 
drug delivery has received increasing attention in the 
pharmaceutical field as it enables improved therapeutic advantages, 
such as ease of dosing administration, patient compliance and 
flexibility in formulation. Floating drug delivery system is low 
density system that has sufficient buoyancy to float over the gastric 
contents and remain buoyant in the stomach without affecting the 
gastric emptying rate for a prolonged period of time. While the 
system is floating on the gastric contents, the drug is released slowly 
at the desired rate. After release of drug, the residual system is 
emptied from the stomach. This results in an increased gastric 
retention time and a better control of the fluctuations in plasma 
drug concentration In situ gel is a type of this system forming 
polymeric formulations is in sol form before administration in the 
body, but undergo gelation in situ to form a gel when in contact with 
physiological fluids. Various triggers to induce gelation include pH, 
ions and temperature [1, 2]. The gelling of this solution is to be 
achieved in gastric environment [3, 4, 5]. The present work deals 
with formulation, optimization and evaluation of pH triggered 
floating oral in situ gel in which sodium alginate has been used as a 
gelling polymer and HPMC K100M as a release retardant polymer 
for controlled release. 
Itopride hydrochloride (ITO) is an oral prokinetic agent used in the 
treatment of gastric motility disorder. It activates the 
gastrointestinal motility through synergism of its dopamine D2 
receptor antagonistic action and acetylcholine esterase-inhibitory 
action. In addition to these actions, ITO has an antiemetic action, 
which is based on its dopamine D2 -receptor antagonistic action. 
The short biological half-life (6 h), 60 % bioavailability and higher 
dosing frequency (50 mg t. i. d.) Makes ITO an ideal candidate for the 
controlled drug delivery [6, 7]. ITO is indicated in various digestive 
conditions such as heartburn, regurgitation, epigastric pain, and 
esophagitis. These conditions include gastro esophageal reflux 
disease, non ulcer dyspepsia, chronic gastritis and a very important 
complication seen in diabetics where in the gastric emptying is 
markedly reduced “i. e”; diabetic gastro paresis.  
MATERIALS AND METHODS  
Materials 
Itopride Hydrochloride was obtained as a gift sample from Ami Life 
Sciences Pvt. Ltd. Baroda Gujarat, India. Sodium alginate was 
obtained from Vijay chemicals Pvt. Ltd, Pune, India. Calcium 
carbonate was obtained from Thermo Fisher Scientific Pvt. Ltd 
Mumbai; India. HPMC K100M was obtained from Vijay Chemicals 
Pvt. Ltd, Pune, India. All other materials and chemicals used were of 
either pharmaceutical or analytical grade. 
Methods 
Preparation of in situ gelling solutions 
Sodium alginate (0.75-1% w/v) and sodium citrate (0.5% w/v) were 
dissolved in deionised water followed by addition of HPMC K100M 
(0.4% w/v) with stirring for 30 min. Calcium carbonate (0.5-1% w/v) 
was separately dissolved in deionised water. Both solutions were 
mixed and the drug was added and stirred till it was completely 
dissolved. The final volume was made up to 100 ml with deionised 
water [8]. 
Experimental design 
Preliminary trials were conducted to identify the concentration of 
sodium alginate and calcium carbonate that formed in situ gels of 
desired strength and floating lag time. Based on this, a 32 simple full 
factorial design having 9 runs (SA1-SA9) (Table 1) were selected. 
Two independent variables, concentration of sodium alginate (X1) 
and calcium carbonate (X2) were selected at 3 levels and dependent 
variables were percent drug release at 1 h (Y1), at 6 h (Y2), gel 
strength (Y3) and T50 % (Y4) time required to release 50 % of loaded 
drug dose. The experimental data was analyzed statistically using 
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Design Expert Software V 9.1 and the main effects and interactions 
were calculated. The effect of independent variables on the response 
parameters was visualised using 3D response plots. Desirability 
approach was employed to locate the optimal settings of the 
formulation variables to obtain desired response. The optimized 
formulation was evaluated for the responses and the experimental 
values obtained were compared with those predicted by the 
mathematical model generated. 
 
Table 1: Formulation combination as per the 32
Ingredient 
 full factorial design for pH sensitive floating oral in situ gel. 
Formulations (Quantity in %w/v) 
SA1 SA2 SA3 SA4 SA5 SA6 SA7 SA8 SA9 
ITO  1  1  1  1  1  1  1  1  1 
Sodium alginate  0.75  0.75  0.75  1  1  1  1.5  1.5  1.5 
Coded level (X1)  -1  -1  -1  0  0  0  +1  +1  +1 
Calcium carbonate  0.5  0.75  1  0.5  0.75  1  0.5  0.75  1 
Coded level (X2)  -1  0  +1  -1  0  +1  -1  0  +1 
HPMC k100M  0.4  0.4  0.4  0.4  0.4  0.4  0.4  0.4  0.4 
Sodium citrate  0.5  0.5  0.5  0.5  0.5  0.5  0.5  0.5  0.5 
Deionised water(up to) 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 
 
Characterization of floating oral in situ gel 
Physical appearance, pH and drug content 
All the formulations were visually checked for their appearance and 
color. The pH of the in situ solution was measured using the 
standardized digital pH meter (Deluxe pH meter 101/EI) at room 
temperature by taking adequate volume in a 50 ml beaker [9]. For 
drug content in situ solution (equivalent to 100 mg of ITO) was taken 
in a volumetric flask. To this 50 ml of 0.1 N HCl was added and shaken 
on the mechanical shaker for 30 min. This was followed by sonication 
for 15 min for complete dispersion of contents and filtration using 
0.45 μm membrane filter. From this solution, 10 ml of sample was 
withdrawn and diluted to 100 ml with 0.1 N HCl. Contents of ITO were 
determined spectrophotometrically at 248 nm using double beam UV-
visible spectrophotometer (LABINDIA 3000+) [10]. 
In vitro gelling capacity 
The in vitro gelling capacity of the formulations was measured by 
placing 5 ml of the gelation solution in simulated gastric fluid (0.1N 
HCl, pH 1.2) in a 15 ml borosilicate glass test tube maintained at 
37±1ºC temperature. The formulation (1 ml) was added slowly by 
placing the pipette at the surface of fluid in the test tube. As the 
solution comes in contact with gelation solution, it is immediately 
converted into a stiff gel like structure. The gelling capacity of solution 
was graded in three categories evaluated on the basis of stiffness of the 
formed gel and time period for which the gel retained its rigidity [11].  
(+) Gels after five min, dispersed within 8 h 
(++) Gels within 60 sec and retains gel structure for 12 h 
(+++) Gels immediately and retains gel structure for more than 12 h. 
In vitro buoyancy test 
In vitro buoyancy was characterized by floating lag time and total 
floating duration. This study was carried out using USP dissolution 
apparatus Type II using 500 ml of 0.1N HCl (pH-1.2) as the medium. 
The test was carried out at 50 rpm at 37±0.5°C. The in situ gelling 
solution (10 ml) was transferred to a petriplate (diameter 2”) using 
a syringe. The plate was then placed on the surface of the medium 
and plunged in to the medium with the moving paddle. The time 
required for the gelled mass to rise to the surface of the dissolution 
medium [floating lag time] and the duration of the time for which 
the gel constantly floated on the dissolution medium [floating 
duration] was noted for each formulation[12-14]. 
Density 
Density of the floating oral in situ gel was determined by using water 
displacement method [15]. To (10 ml) in situ solution, 20 ml of 0.1 N 
HCl (pH 1.2) was added to convert the solution in to gel. Excess of 
HCl was drained off and the gel so formed was weighed. The gel was 
then transferred to a 50 ml measuring cylinder and allowed to settle 
at the base. Distilled water was added up to 50 ml marking of 
measuring cylinder. Volume of water in the presence of gel was 
noted. From the difference in the volumes of water with and without 
gel the volume of gel was obtained i. e. Amount of water displaced by 
the gel was calculated. 
Gel strength 
An in house penetrometer was fabricated based on the method 
explained by Dettmar et al [16] to measure the gel strength. The 
apparatus was comprised a plastic measuring cylinder of 1.2 cm 
radius and a bore of 0.1 mm at its base. A needle, 2 cm in length was 
used to which a nylon thread was tied. Sol (15 ml) was taken in the 
cylinder with temporarily sealed bore followed by addition of 50 ml 
of 0.1 N HCl (pH 1.2) for gelation. After gelation, the HCl was drained 
off by opening bore seal leaving the gel mass in the measuring 
cylinder and the needle was rested on the surface of the gel. At the 
free end of the thread, pan was attached to which the weights were 
added. The gel strength was reported in terms of weight required to 
pass the needle probe through the gel mass[16]. The gel strength 
was calculated using this formula [17], 
Gel strength = Mg/a - - - - - - - - - (1) 
Where, M = weight at which needle passes through the formed gel 
mass. g = gravitational force, taken as 980 cm/s2
Viscosity determination 
; a = Area of 
surfaces. 
The viscosities of the solutions were determined by Brookfield 
viscometer (Model RVDV-II+P). The samples (10 ml) were shared at 
a rate of 100 rpm using S21 spindle at room temperature. Viscosity 
measurement for each sample was done in triplicate, with each 
measurement taking approximately 30s [18]. 
In vitro drug release 
The drug release study was carried out using USP type II paddle type 
apparatus at 37±0.5ºC and at 50 rpm using 900 ml of 0.1 N HCl (pH 
1.2). In situ gel (10 ml) equivalent to 100 mg of ITO was used for the 
test. Sample solution (1 ml) was withdrawn at predetermined time 
intervals, filtered through a 0.45 μm membrane filters, diluted 
suitably and analyzed by UV spectrophotometric LABINDIA 3000+at 
248 nm. Fresh dissolution medium was replaced immediately after 
withdrawal of the test sample to maintain sink condition. The 
dissolution studies were carried out for a period of 12 h [19, 20]. 
The dissolution data were analyzed by DD SolverTM
In-vivo pharmacokinetic studies 
 software for 
mathematical modeling to predict the release kinetics [21, 22]. 
Male Wistar rats, weighing 230–330 g, were fasted for 24 h with free 
access to water. The rats were divided into three groups of six rats 
each, viz., first group served as negative control, second group was 
administered pure ITO solution and third group was administered 
optimized formulation (10mg/kg of animal weight). The rats were 
anaesthetized with the help of ether, and the retro-orbital method 
was used to removal of blood samples. Blood samples were 
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withdrawn from the retro-orbital vein at intervals of 0, 1, 2, 4, 6, 8, 
10, 12 h and analyzed by bioanalytical HPTLC method using a 
mixture of methanol- ammonium acetate (6:4, v/v) as mobile phase 
and detected at λ max 
RESULT AND DISCUSSION 
of 288 nm [23, 24]. A simple protein 
precipitation method was employed for extraction of the drug from 
human plasma using 10% perchloric acid. The protocol for the 
animal experiment was approved by the Animal Ethical Committee 
ref no. (AISSMS/IAEC/13-14/01-28). 
Physical appearance, pH and drug content:  
All the formulations were found to be milky white colored solution. 
The pH was observed in the acceptable range of 7-8. Drug content 
for the prepared formulations was observed with high drug loading 
which is more than 90% showing maximum drug entrapment. The 
drug content was found to be in the range of 90-95%. 
In vitro gelling capacity 
Alginate forms hydrogels by means of calcium, which positions in 
the interstices between G blocks (α-L gluronopyranosyl), leading to 
an ordered conformational structure called “egg-box” array [5]. The 
pre-requisites for in situ gelling system is gelling capacity which is 
defined in terms of speed and extent of gelation. The in situ gel 
should maintain its integrity without dissolving or eroding for 
prolonged periods to facilitate controlled release of drugs locally. 
From the results, it was observed that (SA1-SA3) batches which 
contain low amount of polymer and calcium carbonate form slimy 
gel mass within 5 min which dispersed rapidly. Batches (SA5-SA9) 
form gel within few seconds and remained in their gel state for more 
than 12 h without losing their integrity. 
In vitro buoyancy test 
The time taken by the formulation to emerge on the surface of the 
medium (floating lag time) and the time for which the formulation 
constantly floated on the dissolution medium surface (duration of 
floating) are shown in (Table 2). On contact with gastric 
environment, calcium carbonate effervesced, releasing carbon 
dioxide and calcium ions. Then, gelation and complexation by Ca+2 
ions took place to provide a gel barrier at the surface of the 
formulation. The released carbon dioxide was entrapped in the gel 
network producing a buoyant preparation, which resulted in 
extended floating [25]. The floating properties of the formulation 
mainly depend on calcium carbonate, on increasing the calcium 
carbonate concentration, the floating lag time was reduced and the 
duration of floating was extended. The increasing amounts of Ca+2 
and CO2
Gel strength 
 resulted from the increase in calcium carbonate 
concentration, are responsible for the observed reduction in floating 
lag time and increasing duration of floating. The floating lag time is 
minimum for SA3 and highest for SA1. This is because SA3 contains 
highest concentration of calcium carbonate. Similar was the case 
with formulation SA6 & SA4 and SA9 & SA7 (Table 2). Increase in 
polymer concentration results in an increase in viscosity. Hence time 
taken by the sol to form a cohesive gel mass and to emerge on the 
surface of the medium was lowered. 
Gel strength is indicative of tensile strength of the gelled mass. It 
signifies the ability of the gelled mass to withstand to the in-vivo 
peristaltic movements. The gel strength of the formulation is an 
important variable dependent on the concentration of the gelling 
agent as well as cation source. The high concentration of polymer 
and calcium carbonate resulted in gels with adequate gel strength 
indicating that they can withstand the shear forces likely to be 
encountered in the stomach. Formulations containing low amount of 
sodium alginate formed very weak slimy gel. But with increase in 
calcium carbonate content there was a marginal increase in gel 
strength. This was observed in case of SA1, SA2 & SA3 for which the 
gel strength was in the range of 19.83-53.96 gm/cm2because it 
contains the increasing amount of the calcium carbonate. Similar 
pattern was observed in the batches [SA4-SA6] gel strength 
observed in the range of the 20.17-61.12 gm/cm2 and [SA7-SA9] 
21.36-69.24 gm/cm2
Density 
 (Table: 2). From this result it was revealed that 
the formulation having high gel strength can remained at high 
peristaltic movements. 
The prime requirement of the floating system is that it should have 
density lesser than gastric contents (~1.004 gm/cm3). The density of 
all floating in situ gel formulations was observed less than that of the 
gastric content (Table 2). Density is an important parameter as far as 
the floating properties of the gastroretentive dosage form is 
concerned. The density of all the formulations was recorded and found 
to be lesser than the reported density of gastric fluids. All the 
formulations contain entrapped CO2 and thus were found to have 
excellent buoyancy. The average densities of (SA1-SA9) formulations 
were found to be in the range of 0.670 to 0.862 gm/cm3
Viscosity  
. Lowered the 
density of the formulation can floated over an extended period. 
The rheological properties of the solutions are important in view of 
their proposed oral administration. The solutions showed a marked 
increase in viscosity with increasing concentration of polymer 
(Table 2). The solution showed a marked increase in viscosity with 
increasing concentration of sodium alginate and calcium carbonate 
and also due to the presence of HPMC K100M. The calcium 
carbonate content in the formulation simultaneously increased the 
viscosity since it was present in the formulation as insoluble 
dispersion, an increasing concentration of polymer thus contributing 
to increased viscosity. The order of viscosity of all formulations were 
SA9 > SA8 > SA7 > SA6 > SA5 > SA4 > SA3 > SA2 > SA1. The 
formulations showed a marked increase in viscosity with increasing 
concentration of sodium alginate, calcium carbonate and HPMC 
K100M. It was found to be in the range of 136.1-182.3 cps. 
In-vitro drug release 
The effect of polymer concentration on in vitro drug release from in 
situ gels is depicted in (fig. 1). A significant decrease in rate and 
extent of drug release was observed with the increase in polymer 
concentration, and is attributed to increase in the density of the 
polymer matrix and also increase in the diffusional path length 
which the drug molecules have to traverse. The release of the drug 
from these gels are characterized by an initial phase of high release 
(burst effect) followed by a slower release as the gelation proceeds. 
This bi-phasic pattern of release is a characteristic feature of matrix 
diffusion kinetics. Since the in situ gelling systems are aqueous in 
nature the matrix formed before the complete gelation cross-linking 
is already be in a hydrated state there by circumventing the rate 
limiting step of matrix hydration in the initial stages [26]. 
The dissolution profile of all the batches revealed that 
concentrations of sodium alginate, calcium carbonate and HPMC 
K100M have an important role in drug release pattern. In vitro drug 
release profile is depicted in (fig. 1). Among the 9 formulations 
evaluated, SA1 which contained the lowest proportion of sodium 
alginate and calcium carbonate showed burst release with > 90 % 
drug released in about 4 h though HPMC K100M was also present in 
the formulation. On the other hand formulations SA7, SA8 and SA9 
which contained the highest proportion of sodium alginate, calcium 
carbonate with HPMC K100M displayed a gradual and sustained 
release over a period of 12 h. 
Release kinetics 
Mathematical modelling of the release profiles for the nine 
formulations revealed that dissolution followed Peppas model 
(r2
Statistical Analysis 
=0.9818-0.9955). The value of diffusion exponent ‘n’ for all 
factorial formulations was less than 0.45 (Table 3) indicating Fickian 
drug release which indicates the release of the drug from the matrix 
system. 
Analysis of experimental results was carried out by using Design 
Expert V 9.1 software. The quadratic model was suggested to run the 
design. F-values, P-value and model F-value for percent drug release 
at 1 h, 6 h, gel strength and T50% were obtained from ANOVA. For all 
responses, the Model F-value implied that the quadratic model was 
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significant. The probability values (p≤ 0.05) indicated that all the 
model terms across all the responses were significant. Polynomial 
equations for responses Y1, Y2, Y3 and Y4 depict the relation 
between the factors and responses. The coefficients of various terms 
in the polynomial equations generated by the software give the 
nature and magnitude of the relationship between the variables and 
the responses (Table 4). The concentration of sodium alginate and 
calcium carbonate was found to significantly retard drug release at 1 




Table 2: Floating lag time, Floating duration, Gel strength, density and viscosity of pH triggered floating oral in situ gel (n=3). 






-3 Viscosity ) 
(Cps) 
SA1 + 17±2.1 8 19.89±0.2 0.694±0.1 136.1±0.26 
SA2 + 15±1.2 8 32.77±0.2 0.837±0.5 144.6±0.15 
SA3 + 12±0.8 8 53.96±0.2 0.728±0.5 152.1±1.5 
SA4 ++ 14±0.9 12 20.17±0.2 0.862±0.8 149.5±0.1 
SA5 +++ 12±1.5 12 33.62±0.2 0.759±0.5 158.2±0.20 
SA6 +++ 10±0.2 12 61.12±0.1 0.869±0.3 163.4±0.11 
SA7 +++ 10±1.6 >12 21.36±0.5 0.670±0.3 172.3±0.25 
SA8 +++ 08±2.3 >12 38.49±0.1 0.799±0.5 177.8±0.05 
SA9 +++ 07±1.2 >12 69.24±0.2 0.720±0.1 182.3±0.73 
(+) Gels after five min, dispersed within 8 h, (++) Gels within 60 sec and retains gel structure for 12 h, (+++) Gels immediately and retains gel 
structure for more than 12 h. 
 
 
Fig. 1: In vitro drug release profiles for pH sensitive floating oral in situ gel of batches SA1-SA9 
 
Table 3: The release kinetic data of pH sensitive floating oral in situ gel of ITO batches SA1-SA9. 
Batches Regression value Parameter’s for Peppas equation 
Zero order First order Higuchi Peppas Hixon Crowell n K 
SA1 0.7303 0.9698 0.9814 0.9916 0.9444 0.400 49.860 
SA2 0.6760 0.9946 0.9767 0.9955 0.9684 0.367 54.109 
SA3 0.5425 0.9906 0.9508 0.9945 0.9624 0.323 55.217 
SA4 0.6802 0.9498 0.9786 0.9856 0.9278 0.428 40.116 
SA5 0.6179 0.9144 0.9658 0.9818 0.8717 0.413 35.500 
SA6 0.6269 0.9206 0.9717 0.9821 0.8795 0.418 35.013 
SA7 0.7433 0.9370 0.9813 0.9818 0.9182 0.423 27.678 
SA8 0.6455 0.9383 0.9829 0.9885 0.8990 0.442 30.936 
SA9 0.8034 0.9693 0.9867 0.9891 0.9593 0.443 24.508 
  
Table 4: Summary of results of regression analysis of pH triggered floating oral in situ gel for responses Y1, Y2, Y3 and Y4 
For percent drug release at 1 h 
Model Model F value p value R Adeq. precision 2 Std. deviation  
Quadratic 44.62 0.0051 0.9867 15.564 1.80 
Y1 = 43.32 -10.88*X1 – 0.56*X2 – 3.92*X1*X2 - 2.40* X12 + 0.040*X22
For percent drug release at 6 h 
  
Quadratic 15.54 0.0235 0.9628 9.579 4.65 
Y2=72.21-16.67X1-1.79X2-0.59X1X2-6.45X12+1.62X2
For gel strength 
2  






 -Time required for release of 50% of loaded drug dose 
16.56 0.0215 0.9650 10.506 0.34 
Y4= 2.03+1.23X1+0.14X2+0.18X1X2-0.018X12+0.11X22  
The same is reflected in the 3D response surface plots which depict the relationship between the response and independent variable across a wider 
domain.(fig. 2, 3, 4 and 5). 
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Fig. 2: 3-D Response surface plot showing the influence of 
sodium alginate and calcium carbonate concentration on the 
percent drug release at 1 h. 
 
 
Fig. 3: 3-D Response surface plot showing the influence of 
sodium alginate and calcium carbonate concentration on the 
percent drug release at 6 h. 
 
 
Fig. 4: 3-D Response surface plot showing the influence of 




A numerical optimization technique using the desirability approach 
using the Design Expert software was employed to develop optimum 
formulation with the desired responses. Constraints were set for 
minimizing drug release at 1 h, drug release at 6 h, gel strength and 
T50%
 
Fig. 5: 3-D Response surface plot showing the influence of 
sodium alginate and calcium carbonate concentration on T
 to locate the optimum setting of independent variables. Based 
on the input constraints the optimized in situ gel formula was 
generated by the software which comprised 1 % w/v sodium 
alginate and 1 % w/v of calcium carbonate and 0.4 %w/v HPMC 
K100M. 
50%. 
time required to release 50% of loaded drug dose 
 
The optimized formulation (S1) was evaluated for percentage drug 
release at 1 h, 6 h, gel strength and T50%. A low residual error was 
evident in the observed and predicted responses (0.48, 0.98, 0.93 
and 0.15) with desirability of 0.999 for the optimized formulation. 
Drug release at 1 h, 6 h, gel strength and T50% from optimized batch 
was found to be 28.96 %, 61.62 %, 68.03 gm/cm2and 3.5 h. The 
optimized batch was evaluated further for parameters like pH, gel 
strength and density (Table 5). 
In-vivo studies  
In vivo studies were performed to quantify plasma concentration of 
ITO after oral administration of in situ gel formulation and pure ITO. 
The various pharmacokinetic parameters are presented in (Table 6). 
The plasma concentration time profile of pure drug and formulation 
is represented in (fig. 6). Itopride Hydrochloride was available in 
plasma within an hour after its oral administration with Cmax of 
0.163 µg/ml. Tmax for test formulation was found to be 6 h and Cmax 
was found to be 0.179 µg/ml (Table no 6). The higher Tmax of the 
test formulation suggests slower absorption. This delayed 
absorption of test preparation is due to the sustained release of the 
drug. This indicates control release of drug over 12 h. The total area 
under the curve of AUC 0-12 h
 
 was found to be 1.528, an increase in 
the 90% bioavailability of the formulation was observed than that of 
the plain drug. The elimination rate constant for ITO in the sodium 
alginate in situ gelling system was found to be 0.151/h which was 
23% lower than that for pure drug. The relative bioavailability of 
ITO is 60% due to first-pass effect [27]. It is metabolized in liver by 
N-oxidation to inactive metabolites by the enzyme flavin-containing 
monooxygenase [28]. Thus we may infer that formulating ITO as a 
controlled release formulation using pH triggered in situ gelling 
system. 
 
Fig. 6: In vivo drug release profile of optimum formulation and 
pure drug ITO of pH triggered floating oral in situ gel 
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Table 6: Pharmacokinetic parameters for pH triggered floating oral in situ gel (n=3) 
Parameters Pure Drug Optimized Formulation (S1) 
C µg/ml max 0.163±0.06 0.179±0.08 
T H max 1±0.68 6±1.02 
AUC h. µg/ml 0-12 0.80±0.5 1.528±0.9 
K hele 0.198±0.09 -1 0.151±0.08 
 
CONCLUSION 
Itopride hydrochloride was successfully formulated as a pH 
triggered floating oral in situ gelling system using sodium alginate as 
a natural polymer. The results of 32 full factorial designs revealed 
that the concentration of sodium alginate and concentration of 
calcium carbonate significantly affected on the dependent variables 
like percent drug release at 1 h, 6 h, gel strength and T50%
1. Miyazaki S, Endo K, Kawasaki N, Kubo W, Watanabe H, Attwood 
D. Oral sustained delivery of paracetamol from in situ gelling 
xyloglucan formulations. Drug Del Ind Pharm 2003;29(2):113-9. 
. The 
optimized formulation provided controlled in vitro release of the 
drug over an extended period of 12 h. The drug release from gel 
structure follows a Korsemeyer-Peppas model, which indicates a 
diffusion-controlled release. The optimized formulation can be a 
competent alternative to conventional oral solid dosage form. 
Controlled release oral in situ gel of Itopride Hydrochloride was 
prepared successfully improving its bioavailability. The oral in situ 
gel improves patient compliance by reducing the frequency of the 
dosing. 
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